

How to Understand Sleep and Sleep Problems in Patients with Prader-Willi Syndrome?

Eun Yeon Joo

Department of Neurology, Neuroscience Center, Samsung Medical Center, Samsung Biomedical Research Institute, Sungkyunkwan University School of Medicine, Seoul, Korea

Sleep problems occur frequently among patients with Prader-Willi syndrome (PWS). The most common problem is excessive daytime sleepiness (EDS) that are closely related to sleep-related breathing disorder (SRBD) such as obstructive sleep apnea (OSA) and congenital hypoventilation syndrome. Obesity, craniofacial dysmorphism and muscular hypotonia of patients with PWS may increase the risk of SRBD. Sleep apneas can interrupt the continuity of sleep, and these disruptions result in a decrease in both the quality and quantity of sleep. In addition to SRBD, other sleep disorders have been reported, such as hypersomnia, a primary abnormality of the rapid eye movement (REM) sleep and narcolepsy traits at sleep onset REM sleep. Patients with PWS have intrinsic abnormalities of sleep-wake cycles due to hypothalamic dysfunction. The treatment of EDS and other sleep disorders in PWS are similar to standard treatments. Correction of sleep hygiene such as sufficient amount of sleep, maintenance of regular sleep-wake rhythm, and planned naps are important. After comprehensive evaluation of sleep disturbances, CPAP or surgery should be recommended for treatment of SRBD. Remaining EDS or narcolepsy-like syndrome are controlled by stimulant medication. Bright light therapy might be beneficial for disturbed circadian sleep-wake rhythm caused by hypothalamic dysfunction.

Keywords: Sleep, Excessive daytime sleepiness, Sleep-related breathing disorder, REM sleep abnormalities, Hypothalamic dysfunction

Introduction

Prader-Willi syndrome (PWS) is a genetic disorder in which hypotonia is the predominant feature in infancy, whereas developmental delay, obesity and behavioral problems become more prominent during childhood and adolescence¹. Sleep problems occur frequently among individuals with PWS. Because of the development of obesity, craniofacial dysmorphism and muscular hypotonia, patients with PWS are at a risk of sleep-related breathing disorder (SRBD) such as obstructive sleep apnea (OSA) and congenital hypoventilation syndrome². The most common problem is excessive daytime sleepiness (EDS). Sleep disturbances and sleep apnea were initially listed as a minor diagnostic criterion in the diagnosis of PWS³. Obstructive sleep apnea is associated with increasing body weight. Sleep apnea can interrupt the continuity of sleep, and these disruptions result in a decrease in both the quality and quantity of sleep. EDS can result from this decrease in

sleep efficiency. In addition to SRBD, other sleep disorders have also been reported, such as hypersomnia, a primary abnormality of the circadian rhythm of rapid eye movement (REM) sleep and narcoleptic traits at REM sleep onset^{4,5}. Patients with patients may also present with primary abnormal ventilatory responses to hypoxia and hypercapnia, which might be exacerbated by obesity⁶. Besides, patients with PWS have intrinsic abnormalities of sleep-wake cycles due to hypothalamic dysfunction. Since EDS has been correlated with the intrusion of REM sleep into wakefulness, individuals with PWS may appear to have narcolepsy-like symptoms. This article will review the literature regarding sleep problems in patients with PWS and will suggest the optimal management to improve their health and behavioral disturbances as well as patients and families' quality of life.

Received October 14, 2015; Revised October 20, 2015; Accepted October 31, 2015

Correspondence to: Eun Yeon Joo

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea
Tel: +82-2-3410-3597, Fax: +82-2-3410-0052, E-mail: ejoo@skku.edu

Copyright © 2015. Association for Research of MPS and Rare Diseases

© This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Excessive Daytime Sleepiness in Patients with PWS

Patients with PWS frequently experience significant EDS. Most common cause of EDS is chronic sleep insufficiency, and the next is nocturnal sleep disturbance mainly related to SRBD. Central nervous system hypersomnia such as narcolepsy or idiopathic hypersomnia are the third most common causes of EDS in both adults and children with PWS. In a sleep questionnaire study, EDS was commonly described in children with PWS⁷. It was reported that 20 out of 30 pediatric PWS patients were given a score by their caregivers of more than 10 on the Epworth Sleepiness Scale, indicating significant EDS⁸. Objectively, moderate to severe sleepiness was noted on the MSLT in 11 out of 18 adult PWS patients⁹. This sleepiness seems to be predominantly in inactive and unengaging situations. Dissimilar results have been reported with respect to correlating EDS in PWS with weight. However, it might be certain that the sleepiness experienced by PWS patients is responsible for the behavioral disturbances observed in PWS patients.

Sleep Related Breathing Disorders in Patients with PWS

OSA is the most frequent SRBD reported in PWS. It may be caused by obesity, sticky saliva, kyphoscoliosis, or adenotonsillar hypertrophy in combination with the narrow upper airways in PWS. Hypotonia of the respiratory muscles may also play a role. Recently, it has been demonstrated that non-obese pre-pubertal PWS children have mainly central sleep apnea and only rarely OSAS during thenight¹⁰. Patients with PWS are at increased risk for sleep-disordered breathing, in particular OSA and hypoventilation, with weight being a prominent risk factor. Arousal and cardiorespiratory responses to rapidly developing hypoxia and hypercapnia are also absent, decreased, and/or delayed in PWS compared with control subjects of similar age, sex, and BMI¹¹. These blunted hypoxic and hypercarbic responses in PWS may suggest potential deficiencies in peripheral chemoreceptors or even central respiratory mechanisms in PWS, which may impact on all forms of SRBD¹². OSA may lead to several complications, such as systemic hypertension, cardiovascular disease, and cor pulmonale. Cor pulmonale plays an important role in the morbidity and mortality of patients with PWS. Rapid eye movement sleep abnormalities and EDS are common in PWS and are considered a primary disorder. However, SRBD may disrupt sleep and induce ESD in PWS. In patients with PWS, OSA is associated with behavioral disturbances, such as autistic-related behavior

and impulsiveness¹³. A recent study in young PWS infants found that OSAS was associated with lower mental development¹⁴.

SRBD and Growth Hormone Therapy

Growth hormone (GH) has become an approved treatment in PWS to improve linear growth, lean-to-fat ratio, mobility, behavior, and quality of life in PWS¹⁵. GH may lead to respiratory failure in PWS patients include an increase in the size of lymphoid and soft tissues in the upper respiratory tract with GH therapy, an increase in metabolic rate with increased oxygen demand and ventilator load, and a normalization of previously decreased hydration, which increases volume load¹⁵. It is suggested that close attention be made to obesity and sleep and breathing problems both before and after commencement of GH treatment, with a low threshold for ear, nose, and throat assessment and polysomnography.

REM Sleep Abnormalities in Patients with PWS

Several studies have documented the presence of significant REM sleep dysregulation in PWS in the form of shortened REM latency, and increased prevalence of SOREMPs on overnight polysomnography or the multiple sleep latency test (MSLT)¹⁶⁻¹⁸. Such REM dysregulation implies a disruption in the circadian rhythms of PWS patients or a dysfunction in fundamental sleep-wake mechanisms. We also observed that a shorter sleep latency and REM latency in the PWS group¹⁹. It suggested that REM sleep abnormalities in children with PWS than normal children. Such REM dysregulation may be linked with the abnormal thermoregulation observed in PWS, pointing to hypothalamic dysfunction as the cause of such dysregulation⁵.

Hypothalamic Dysfunction and Narcolepsy-like Syndrome in Patients with PWS

The presence of REM abnormalities and EDS not otherwise explained suggests the presence not only of a narcolepsy-like syndrome in patients with PWS, but narcolepsy itself. The majority of studies, however, have not reported the presence of narcolepsy symptoms in their PWS samples, including cataplexy, hypnagogic/hypnopompic hallucinations, and sleep paralysis²⁰. Hypocretin (orexin) is a peptide neurotransmitter found in the dorsal and lateral hypothalamus. Narcolepsy in humans has been associated with decreased hypocretin CSF levels and degeneration of hypocretin neurons. In addition to its role in sleep regulation,




Fig. 1. Actigraphy and actogram of a patient with disturbed sleep-wake pattern. A patient is a 22 year-old college student who suffered from sleep onset insomnia and excessive daytime sleepiness. A week of actogram showed irregular sleep-wake pattern combined with delayed sleep-wake cycles. Data was recorded by Actiwatch Spectrum 2 (Philips, Andover, MA, USA) Blue bars represent sleep time recorded by actigraphy. Dark-blue bar indicate the time of taking off the watch.

hypocretin/orexin has been associated with a number of other effects including appetite regulation, autonomic and endocrine function, and pleasure-reward pathways²¹. Mignot et al.²² identified a 16-year-old with PWS with low levels (≤ 110 pg/mL by direct radioimmunoassay) of CSF hypocretin comparable to that of narcolepsy. Based on the limited evidence it seems that the sleepiness in PWS is associated with a deficiency of hypocretin/orexin in the hypothalamus, but not necessarily a degeneration of hypocretin neurons as is seen in narcolepsy.

Disturbed sleep-wake pattern and irregular sleep cycles in PWS are responsible for hypothalamic dysfunction, in particular, suprachiasmatic nucleus located in anterior hypothalamus. It is well-known that bright light therapy with scheduled melatonin administration may normalize disturbed sleep-wake cycle²³. Circadian abnormalities are monitored with actigraphy²⁴ (Fig. 1). Actigraphic data were recorded in eight children with the rare genetic condition mucopolysaccharidosis (MPS) type III over 7–10 days and showed impairment in circadian rhythm functioning in children with this condition²⁵. Recently, two studies with small numbers of PWS children demonstrated that children with PWS had a shorter sleep latency but more time awake in the night than normal children and have similar total sleep time and morning wake time compared with controls^{26,27}. However, disturbed sleep-wake patterns were not evident in those studies. In future, a larger number of study subjects and age-adjusted study protocol would

be required to obtain a definite conclusion.

Treatment of Sleep Problems in Patients with PWS

The first intervention is to improve sleep hygiene by shaping behavior to assure the appropriate amount of sleep and to supplement this with planned naps, if necessary. The second intervention is to treat the source of sleep disruption; CPAP is needed for OSA or intermittent hypoxemia. However, cases where the treatment of SRBD in PWS does not alleviate daytime sleepiness²⁸⁻³², further reinforce the hypothesis that SRBD alone cannot account for the presence of daytime sleepiness in this population. Then, the daytime use of stimulant medication (methylphenidate) and/or modafinil are recommended. Besides, weight loss and upper airway surgery might be beneficial for sleep problems in PWS³³. Identification and treatment of sleep problems in patients with PWS would definitely improve physical and mental health as well as quality of life of families³⁴.

Conclusion

EDS is a frequent and significant symptom of patients with PWS. There are a number of risk factors that predispose them to SRBD, but OSA in itself does not account for all of the EDS experienced by such patients. Hypothalamic dysfunction is implicated in patients with PWS, and such dysfunction likely explain narcolepsy-like syndrome and circadian rhythm sleep-wake disorder observed in PWS patients. It is important for both physician and parents/care providers pay more attention on sleep problems in patients with PWS.

References

1. Prader, A., Labhart, A. and Stuber, H. W. Einsyndrom von adipositas, kleinwuchs, kryptorchismus und oligophrenien-achmyatonieartigemzustandimNeugeborenenalter. Schweiz. Med. Wochenschr 1956;86:1260-1.
2. Manni R, Politini L, Nobili L, Ferrillo F, Livieri C, Vnenselli E, et al. Hypersomnia in the PraderWilli syndrome: clinical-electrophysiological features and underlyingfactors. Clin. Neurophysiol 2001;112:800-5.
3. Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY, et al. Prader-Willi Syndrome: Consensus diagnostic criteria. Pediatrics 1993;91:398-402.
4. Clarke DJ, Waters J, Corbett JA. Adults with Prader-Willi-syndrome: abnormalities of sleep and behaviour. JR Soc Med

- 1989;82:21-4.
5. Vela-Bueno A, Kales A, Soldatos CR, Dobladez-Blanco B, Campos-Castelo J, Espino-Hurtado P, et al. Sleep in the Prader-Willi syndrome clinical and polygraphic findings. *Arch Neurol* 1984;41:294-6.
 6. Reynolds CF III, Coble PA, Kupfer DJ, and Holzer BC. Application of the multiple sleep latency test in disorders of excessive sleepiness. *Electroencephalogr. Clin Neurophysiol* 1982;53:443-52.
 7. Cotton S, Richdale A. Brief report: parental descriptions of sleep problems in children with autism, Down syndrome, and Prader-Willi syndrome. *Res Dev Disabil* 2006;27:151-61.
 8. Williams K, Scheimann A, Sutton V, Hayslett E, Glaze DG. Sleepiness and sleep disordered breathing in Prader-Willi syndrome: relationship to genotype, growth hormone therapy, and body composition. *J Clin Sleep Med* 2008;4:111-18.
 9. Priano L, Grugni G, Miscio G, Guastamacchia G, Toffolet L, Sartorio A, et al. Sleep cycling alternating pattern (CAP) expression is associated with hypersomnia and GH secretory pattern in Prader-Willi syndrome. *Sleep Med* 2006;7:627-33.
 10. Festen DAM, de Weerd AM, van den Bossche RAS, Joosten K, Hoeve H, Hokken-Koelega AC. Sleep-related breathing disorders in prepubertal children with Prader-Willi syndrome and effects of growth hormone treatment. *J Clin Endocrinol Metab* 2006;91:4911-5.
 11. Festen D, Hokken-Koelega A. Breathing disorders in Prader-Willi syndrome: the role of obesity, growth hormone treatment and upper respiratory tract infections. *Expert Rev Endocrinol Metab* 2007;2:529-37.
 12. Barbera J et al. *Sleep and Mental Illness*, eds. S. R. Pandi-Perumal and M. Kramer. Cambridge University Press 2010.
 13. O'Donoghue F, Camfferman D, Kennedy J, Martin A, Couper T, Lack L, et al. Sleep-disordered breathing in Prader-Willi syndrome and its associations with neurobehavioral abnormalities. *J Pediatr* 2005;147:823-9.
 14. Festen DA, Wevers M, de Weerd AW, van den Bossche RA, Duivenvoorden HJ, Otten BJ, et al. Psychomotor development in infants with Prader-Willi syndrome and associations with sleep-related breathing disorders. *Pediatr Res* 2007;62:221-4.
 15. Stafler P, Wallis C. Prader-Willi syndrome: who can have growth hormone? *Arch Dis Child*. 2008;93:341-5.
 16. Kaplan J, Fredrickson PA, Richardson JW. Sleep and breathing in patients with the Prader-Willi syndrome. *Mayo Clin Proc* 1991;66:1124-6.
 17. Hertz G, Cataletto M, Feinsilver SH, Angulo M. Sleep and breathing patterns in patients with Prader-Willi syndrome (PWS): effects of age and gender. *Sleep* 1993;16:366-71.
 18. Helbing-Zwanenburg B, Kamphuisen HA, Mourtazaev MS. The origin of excessive daytime sleepiness in the Prader-Willi syndrome. *J Intellect Disabil Res* 1993;37:533-41.
 19. Joo EY, Hong SB, Sohn YB, Kwak MJ, Kim SJ, Choi YO, et al. Plasma adiponectin level and sleep structures in children with Prader-Willi syndrome. *J Sleep Res* 2010;19:248-54.
 20. Vgontzas AN, Bixler EO, Kales A, Cengulfiond A, Rogan PK, Mascari M, et al. Daytime sleepiness and REM abnormalities in Prader-Willi syndrome: evidence of generalized hypoarousal. *Int J Neurosci* 1996;87:127-39.
 21. Ganjavi H, Shapiro CM. Hypocretin/orexin: a molecular link between sleep, energy regulation, and pleasure. *J Neuropsychiatry Clin Neurosci* 2007;19:413-19.
 22. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. *Arch Neurol* 2002;59:1553-62.
 23. Zee PC, Turek FW. Respect the clock. *Sleep Med Rev* 2013;17:395-7
 24. Ancoli-Israel S, Martin JL, Blackwell T, Buenaver L, Liu L, Meltzer LJ, et al. *The SBSM Guide to Actigraphy Monitoring: Clinical and Research Applications*. *Behav Sleep Med* 2015; 17(13 Suppl 1):S4-S38.
 25. Mumford RA, Mahon LV, Jones S, Bigger B, Canal M, Hare DJ. Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome). *J Neurodev Disord* 2015;7:31.
 26. Gibbs S, Wiltshire E, Elder D. Nocturnal sleep measured by actigraphy in children with Prader-Willi syndrome. *J Pediatr* 2013;162:765-9.
 27. Kawada T. Sleep evaluation by actigraphy for children with Prader-Willi syndrome. *J Pediatr*. 2013;163:307.
 28. Clift S, Dahlitz M, Parkes JD. Sleep apnoea in the Prader-Willi syndrome. *J Sleep Res* 1994;3:121-6.
 29. Vgontzas AN, Bixler EO, Kales A, Vela-Bueno A. Prader-Willi syndrome: effects of weight loss on sleep disordered breathing, daytime sleepiness and REM sleep disturbance. *Acta Paediatr* 1995;84:813-14.
 30. Harris JC, Allen RP. Is excessive daytime sleepiness characteristic of Prader-Willi syndrome? The effects of weight change. *Arch Pediatr Adolesc Med* 1996;150:1288-93.
 31. Friedman E, Ferber R, Wharton R, Dietz W. Sleep apnea in the Prader-Willi syndrome. *Sleep Res* 1984;13:142.

32. Hiroe Y, Inoue Y, Higami S, Suto Y, Kawahara R. Relationship between hypersomnia and respiratory disorder during sleep in Prader-Willi syndrome. *Psychiatry Clin Neurosci* 2000;54:323-5.
33. Giordano L, Toma S, Palonta F, Teggi R, Zucconi M, Di Candia S, et al. Obstructive sleep apnea in Prader-Willi syndrome: risks and advantages of adenotonsillectomy. *Pediatr Med Chir* 2015;28;37(2).
34. Wong CP, Ng DK, Ma TM, Chau C, Chow PY, Kwok KL. Improvement in quality of life after adenotonsillectomy in a child with Prader Willi syndrome. *Sleep Breath* 2010;14:167-70.